POINT Biopharma Global Inc., (PNT) News
Filter PNT News Items
PNT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PNT News From Around the Web
Below are the latest news stories about POINT BIOPHARMA GLOBAL INC that investors may wish to consider to help them evaluate PNT as an investment opportunity.
POINT Biopharma to Participate in Upcoming Investor ConferencesINDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor conferences: Guggenheim 5th Annual Oncology ConferenceFormat: Fireside Chat and 1x1 MeetingsLocation: New York, NYDate: Wednesday, February 8, 2023Time: 2:10 pm ET SVB Securities Global Biopharma |
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH TrialEnrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidanceINDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the completion of enrollment for the randomization phase in the pivotal phase 3 SPLASH trial, on schedule and meeting previous guidance. SPLASH is a multi- |
POINT Biopharma Announces Closing of Agreements with Lantheus HoldingsINDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH). Under the terms of the agreements, POINT will receive the initial $260 million in upfront payments |
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with ImmunotherapyCombining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model 177Lu-PNT6555, the lead of the PNT2004 pan-cancer fibroblast activation protein-α (FAP-α) targeted program, is currently in a phase 1 trial INDIANAPOLIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development |
POINT Biopharma Global (PNT) Gets a Buy from JonesTradingIn a report released today, Justin Walsh from JonesTrading maintained a Buy rating on POINT Biopharma Global (PNT - Research Report), with a price target of $18.00. The company's shares closed yesterday at $5.72.According to TipRanks, Walsh is an analyst with an average return of -29.6% and a 21.88% success rate. Walsh covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Actinium Pharmaceuticals, and Plus Therapeutics.Currently, the analyst consensus on POINT Biopharma Global is a Strong Buy with an average price target of $19.57, implying a 242.13% upside from current levels. |
Truist Financial Sticks to Its Buy Rating for POINT Biopharma Global (PNT)Truist Financial analyst Nicole Germino maintained a Buy rating on POINT Biopharma Global (PNT - Research Report) today and set a price target of $14.00. The company's shares opened today at $5.96.Germino covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Assembly Biosciences, and Fusion Pharmaceuticals. According to TipRanks, Germino has an average return of -25.3% and a 20.00% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for POINT Biopharma Global with a $18.43 average price target, implying a 209.23% upside from current levels. |
Stocks Cool Off From Last Week's RallyStocks are starting the week off lower, unable to build off of last week's impressive rally. |
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus HoldingsINDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the comme |
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticals Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding certain territories1, to two late-stage therapeutic agents NORTH BILLERICA, Mass. and INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (”Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through |
POINT Biopharma Global (PNT) Receives a Buy from JonesTradingJonesTrading analyst Justin Walsh maintained a Buy rating on POINT Biopharma Global (PNT - Research Report) today and set a price target of $22.00. The company's shares opened today at $7.99.According to TipRanks, Walsh is an analyst with an average return of -38.1% and a 16.67% success rate. Walsh covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Plus Therapeutics, and Actinium Pharmaceuticals.POINT Biopharma Global has an analyst consensus of Strong Buy, with a price target consensus of $20.43, representing a 155.69% upside. In a report released on October 10, Oppenheimer also initiated coverage with a Buy rating on the stock with a $20.00 price target. |